Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Type C Meeting Timings

<< Previous

Bullboard Posts

Next >>

Comment by ENEMENEMYNEMOon May 09, 2024 7:48pm

69 Views

Post# 36032476

RE:RE:RE:RE:RE:Type C Meeting Timings

Very true. Never seen a biotech not immediately post a NR when the FDA grants a meeting and the date of said meeting.

No fault of Matt here though because they don't have a date yet as their request has not been formally accepted. He just had this 1st Q Financials all done up, cocky pr-ic-k and didn't want to change it in expectation of a date. He ain't got it HAHA

<< Previous

Bullboard Posts

Next >>

The deep connection between mining and First Nations in Canada